Stockscreener 앱 받기
54.84
4.24%
-2.2212
전일 마감가:
$57.06
열려 있는:
$55.59
하루 거래량:
7.11M
Relative Volume:
0.56
시가총액:
$9.30B
수익:
$640.44M
순이익/손실:
$-743.28M
주가수익비율:
-4.8578
EPS:
-11.2888
순현금흐름:
$-206.93M
1주 성능:
+1.62%
1개월 성능:
+28.32%
6개월 성능:
+22.79%
1년 성능:
+0.00%
1일 변동 폭
$52.80
$55.75
1주일 범위
$50.05
$58.68
52주 변동 폭
$22.89
$91.45
Tempus Ai Inc Stock (TEM) Company Profile
명칭
Tempus Ai Inc
전화
800-976-5448
주소
600 WEST CHICAGO AVENUE, CHICAGO
TEM을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
54.77 | 9.30B | 640.44M | -743.28M | -206.93M | -11.29 |
|
VEEV
Veeva Systems Inc
|
238.37 | 36.73B | 2.75B | 714.14M | 1.09B | 4.33 |
|
DOCS
Doximity Inc
|
59.47 | 10.64B | 516.85M | 174.11M | 217.38M | 0.87 |
|
HQY
Healthequity Inc
|
92.38 | 7.43B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
41.35 | 6.34B | 906.14M | -52.62M | 89.62M | -0.3621 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-21 | 개시 | BTIG Research | Buy |
| 2025-02-25 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2025-02-12 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 재개 | TD Cowen | Buy |
| 2024-12-13 | 개시 | Wolfe Research | Outperform |
| 2024-12-09 | 개시 | Guggenheim | Buy |
| 2024-11-11 | 다운그레이드 | Stifel | Buy → Hold |
| 2024-10-02 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2024-08-12 | 개시 | Piper Sandler | Neutral |
| 2024-07-09 | 개시 | BofA Securities | Buy |
| 2024-07-09 | 개시 | JP Morgan | Overweight |
| 2024-07-09 | 개시 | Longbow | Buy |
| 2024-07-09 | 개시 | Loop Capital | Buy |
| 2024-07-09 | 개시 | Morgan Stanley | Overweight |
| 2024-07-09 | 개시 | Needham | Buy |
| 2024-07-09 | 개시 | Stifel | Buy |
| 2024-07-09 | 개시 | TD Cowen | Buy |
| 2024-07-09 | 개시 | William Blair | Outperform |
모두보기
Tempus Ai Inc 주식(TEM)의 최신 뉴스
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - The Globe and Mail
AI Healthcare Boom Gains Speed as Regulators and Innovators Align - Benzinga
Tempus Announces Notetaker, its AI-Powered Clinical Assistant for Psychiatry - Yahoo Finance
Tempus exec-founded Pathos AI launched a $400M funding round. It's already filling up. - Crain's Chicago Business
Pathos AI gets AstraZeneca funding as biotech plans to raise up to $400M - Endpoints News
Think It's Too Late to Buy Tempus AI? Here's the Biggest Reason Why There's Still Time. - Yahoo Finance
AI-Powered Imaging Diagnostics Market: Growth, Trends & - openPR.com
Tempus selects TIME Network for Phase I clinical trials - Yahoo Finance
Tempus TIME Network Expands Support of Phase I Clinical Trials To Accelerate Activation and Enrollment - Yahoo Finance
Is This the Best Nancy Pelosi Stock to Buy After a 40% Pullback? - The Globe and Mail
Tempus AI publishes xF+ assay study results in Journal of Molecular Diagnostics - TipRanks
Tempus Publishes Study Validating the Benefits of xF+, its Comprehensive Liquid Biopsy Assay for Therapy Selection - The Joplin Globe
Tempus AI Stock Surges 43% in Q1: Buy Now or Wait for Earnings? - MSN
Press Release Service: Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - CRISPR Medicine News
8 Top Nancy Pelosi Stocks to Buy - US News Money
tempus AI Inc Class A call volume above normal and directionally bullish - TipRanks
Tempus AI Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - marketscreener.com
Analysts Split on High-Stakes ‘Call Option’ for Tempus AI Stock (TEM) - TipRanks
Tempus AI introduces Loop for accelerated cancer target discovery - Investing.com
Tempus AI introduces Loop for accelerated cancer target discovery By Investing.com - Investing.com UK
Tempus Introduces Loop, an AI-Powered Target Discovery and Validation Platform - Business Wire
Why Tempus AI Inc. (TEM) Soared Last Week - Insider Monkey
Tempus Announces 18 Abstracts Accepted for Presentation at the American Association for Cancer Research Annual Meeting 2025 - 01net
Tempus AI Stock (TEM) Surges over 14% in a Day – What’s Next for Investors? - The Globe and Mail
The Zacks Analyst Blog Highlights Tempus AI, AstraZeneca, iRhythm Technologies and SOPHiA GENETICS - Yahoo Finance
Tempus AI to Report First Quarter 2025 Financial Results on May 6 - marketscreener.com
Tempus AI Stock Sees 21% Gain in 3 Days: Is it a Buy After AZN Deal? - MSN
Avidicure’s $50M seed round; Flagship’s new AI company that detects disease - Endpoints News
Tempus to Report First Quarter 2025 Financial Results on May 6 - Business Wire
Beyond The Numbers: 9 Analysts Discuss Tempus AI Stock - Benzinga
AstraZeneca enters $200m AI cancer pact with Tempus and Pathos - Pharmaceutical Technology
AstraZeneca joins Tempus, Pathos in cancer AI project - Pharmaphorum
Tempus partners with AstraZeneca and Pathos for oncology AI model - World Pharmaceutical Frontiers
These 10 Firms Topped Wednesday’s Trading - Insider Monkey
Tempus AI, Inc. (TEM): A Bull Case Theory - MSN
Why Tempus AI Inc. (TEM) Went Up On Wednesday - Insider Monkey
Tempus AI shares surge on new oncology partnerships By Investing.com - Investing.com India
Tempus AI shares surge on new oncology partnerships - Investing.com
Tempus expands partnership with AstraZeneca to build oncology model - MSN
AstraZeneca joins three-way $200M AI oncology deal - FirstWord Pharma
Tempus AI jumps after multi-year deals with AstraZeneca, Pathos AI - TradingView
Why Tempus AI Stock Is Skyrocketing Today - MSN
Tempus AI Is Skyrocketing Today -- Is the Stock a Buy Right Now? - MSN
Is Tempus AI, Inc. (TEM) the Best Nancy Pelosi Stock To Invest In Now? - Insider Monkey
Tempus inks $200 million in AstraZeneca, Pathos AI deals for oncology model - Crain's Chicago Business
Tempus Ai Inc (TEM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.13%
1.91%
자본화:
|
볼륨(24시간):